175 related articles for article (PubMed ID: 11044115)
1. Genotypic, phenotypic, and modeling studies of a deletion in the beta3-beta4 region of the human immunodeficiency virus type 1 reverse transcriptase gene that is associated with resistance to nucleoside reverse transcriptase inhibitors.
Winters MA; Coolley KL; Cheng P; Girard YA; Hamdan H; Kovari LC; Merigan TC
J Virol; 2000 Nov; 74(22):10707-13. PubMed ID: 11044115
[TBL] [Abstract][Full Text] [Related]
2. Augmentation of human immunodeficiency virus type 1 subtype E (CRF01_AE) multiple-drug resistance by insertion of a foreign 11-amino-acid fragment into the reverse transcriptase.
Sato H; Tomita Y; Ebisawa K; Hachiya A; Shibamura K; Shiino T; Yang R; Tatsumi M; Gushi K; Umeyama H; Oka S; Takebe Y; Nagai Y
J Virol; 2001 Jun; 75(12):5604-13. PubMed ID: 11356968
[TBL] [Abstract][Full Text] [Related]
3. Deletions in the beta3-beta4 hairpin loop of HIV-1 reverse transcriptase are observed in HIV-1 isolated from subjects during long-term antiretroviral therapy.
Ross L; Johnson M; Ferris RG; Short SA; Boone LR; Melby TE; Lanier R; Shaefer M; St Clair M
J Hum Virol; 2000; 3(3):144-9. PubMed ID: 10881994
[TBL] [Abstract][Full Text] [Related]
4. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
[TBL] [Abstract][Full Text] [Related]
5. Insertions and deletions in HIV-1 reverse transcriptase: consequences for drug resistance and viral fitness.
Menéndez-Arias L; Matamoros T; Cases-González CE
Curr Pharm Des; 2006; 12(15):1811-25. PubMed ID: 16724949
[TBL] [Abstract][Full Text] [Related]
6. Multidrug resistance genotypes (insertions in the beta3-beta4 finger subdomain and MDR mutations) of HIV-1 reverse transcriptase from extensively treated patients: incidence and association with other resistance mutations.
Tamalet C; Yahi N; Tourrès C; Colson P; Quinson AM; Poizot-Martin I; Dhiver C; Fantini J
Virology; 2000 May; 270(2):310-6. PubMed ID: 10792990
[TBL] [Abstract][Full Text] [Related]
7. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
Chen R; Yokoyama M; Sato H; Reilly C; Mansky LM
J Virol; 2005 Sep; 79(18):12045-57. PubMed ID: 16140780
[TBL] [Abstract][Full Text] [Related]
8. Impact of human immunodeficiency virus type 1 reverse transcriptase inhibitor drug resistance mutation interactions on phenotypic susceptibility.
Trivedi V; Von Lindern J; Montes-Walters M; Rojo DR; Shell EJ; Parkin N; O'Brien WA; Ferguson MR
AIDS Res Hum Retroviruses; 2008 Oct; 24(10):1291-300. PubMed ID: 18844463
[TBL] [Abstract][Full Text] [Related]
9. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
Zhang Z; Walker M; Xu W; Shim JH; Girardet JL; Hamatake RK; Hong Z
Antimicrob Agents Chemother; 2006 Aug; 50(8):2772-81. PubMed ID: 16870771
[TBL] [Abstract][Full Text] [Related]
10. Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.
Varghese V; Mitsuya Y; Shahriar R; Bachmann MH; Fessel WJ; Kagan RM; Shafer RW
Antimicrob Agents Chemother; 2009 May; 53(5):2196-8. PubMed ID: 19223644
[TBL] [Abstract][Full Text] [Related]
11. Increased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-Acid insert in the reverse transcriptase.
van der Hoek L; Back N; Jebbink MF; de Ronde A; Bakker M; Jurriaans S; Reiss P; Parkin N; Berkhout B
J Virol; 2005 Mar; 79(6):3536-43. PubMed ID: 15731248
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations.
White KL; Chen JM; Margot NA; Wrin T; Petropoulos CJ; Naeger LK; Swaminathan S; Miller MD
Antimicrob Agents Chemother; 2004 Mar; 48(3):992-1003. PubMed ID: 14982794
[TBL] [Abstract][Full Text] [Related]
13. A novel genotype encoding a single amino acid insertion and five other substitutions between residues 64 and 74 of the HIV-1 reverse transcriptase confers high-level cross-resistance to nucleoside reverse transcriptase inhibitors. Abacavir CNA2007 International Study Group.
Rakik A; Ait-Khaled M; Griffin P; Thomas TA; Tisdale M; Kleim JP
J Acquir Immune Defic Syndr; 1999 Oct; 22(2):139-45. PubMed ID: 10843527
[TBL] [Abstract][Full Text] [Related]
14. Mechanistic basis of zidovudine hypersusceptibility and lamivudine resistance conferred by the deletion of codon 69 in the HIV-1 reverse transcriptase coding region.
Kisic M; Mendieta J; Puertas MC; Parera M; Martínez MA; Martinez-Picado J; Menéndez-Arias L
J Mol Biol; 2008 Oct; 382(2):327-41. PubMed ID: 18662701
[TBL] [Abstract][Full Text] [Related]
15. An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidine.
Hooker DJ; Tachedjian G; Solomon AE; Gurusinghe AD; Land S; Birch C; Anderson JL; Roy BM; Arnold E; Deacon NJ
J Virol; 1996 Nov; 70(11):8010-8. PubMed ID: 8892925
[TBL] [Abstract][Full Text] [Related]
16. Reduced susceptibility of human immunodeficiency virus type 1 (HIV-1) from patients with primary HIV infection to nonnucleoside reverse transcriptase inhibitors is associated with variation at novel amino acid sites.
Brown AJ; Precious HM; Whitcomb JM; Wong JK; Quigg M; Huang W; Daar ES; D'Aquila RT; Keiser PH; Connick E; Hellmann NS; Petropoulos CJ; Richman DD; Little SJ
J Virol; 2000 Nov; 74(22):10269-73. PubMed ID: 11044070
[TBL] [Abstract][Full Text] [Related]
17. Variants other than aspartic acid at codon 69 of the human immunodeficiency virus type 1 reverse transcriptase gene affect susceptibility to nuleoside analogs.
Winters MA; Merigan TC
Antimicrob Agents Chemother; 2001 Aug; 45(8):2276-9. PubMed ID: 11451685
[TBL] [Abstract][Full Text] [Related]
18. Two Coselected Distal Mutations in HIV-1 Reverse Transcriptase (RT) Alter Susceptibility to Nonnucleoside RT Inhibitors and Nucleoside Analogs.
Boyer PL; Melody K; Smith SJ; Dunn LL; Kline C; Fischer DK; Dwivedi R; Clark P; Hughes SH; Ambrose Z
J Virol; 2019 Jun; 93(11):. PubMed ID: 30894467
[TBL] [Abstract][Full Text] [Related]
19. Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type I found in Brazilian patients failing HAART.
Caride E; Brindeiro R; Hertogs K; Larder B; Dehertogh P; Machado E; de Sá CA; Eyer-Silva WA; Sion FS; Passioni LF; Menezes JA; Calazans AR; Tanuri A
Virology; 2000 Sep; 275(1):107-15. PubMed ID: 11017792
[TBL] [Abstract][Full Text] [Related]
20. Cross-resistance analysis and molecular modeling of nonnucleoside reverse transcriptase inhibitors targeting drug-resistance mutations in the reverse transcriptase of human immunodeficiency virus.
Yang SS; Pattabiraman N; Gussio R; Pallansch L; Buckheit RW; Bader JP
Leukemia; 1997 Apr; 11 Suppl 3():89-92. PubMed ID: 9209308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
